Onconetix Inc ONCO

US Biotechnology

$1.03 ▲ +13.08% (+$0.12)

⬆️ Above Yest. High 🎈 Low Float 🎢 High Beta

Open $1.12

Prev Close $0.91

Day Range $1.00 – $1.42

52W Range $0.59 – $209.50

Market Cap $4.51M

Beta 2.61

EPS (TTM) $-200.08

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2022-02-18
Shares Out.	3,950,000
Website	onconetix.com/ ↗
Phone	13024977115
Employees	2
Revenue	$17,120
Gross Profit	$4,303
Net Income	-$2.9M
Free Cash Flow	-$10.3M
Total Assets	$16.4M
Total Liabilities	$3.0M
Equity	$13.5M

About Onconetix Inc

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Onconetix Inc is a publicly traded company under the ticker symbol ONCO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.